Renzapride

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H22ClN3O2
Molecular Weight	323.818
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(C=C(Cl)C(N)=C1)C(=O)N[C@@H]2CC[N@@]3CCC[C@@H]2C3

InChI

InChIKey=GZSKEXSLDPEFPT-LNUXAPHWSA-N

InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10?,14-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H22ClN3O2
Molecular Weight	323.818
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18922103 | https://www.ncbi.nlm.nih.gov/pubmed/18284648 | https://clinicaltrials.gov/ct2/show/NCT00268879 | https://clinicaltrials.gov/ct2/show/NCT00607971 | https://www.ncbi.nlm.nih.gov/pubmed/18034998

Renzapride (BRL-24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist. This compound has a stimulatory effect on gastrointestinal motility and transit. Renzapride has been evaluated for use in treatment of irritable bowel syndrome (IBS). Data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome. Phase III clinical trials investigated if this drug could help alleviate the symptoms associated with this type of IBS. However, one phase III study has been terminated due to inefficient efficacy (compared to placebo).

Approval Year

PubMed

Title	Date	PubMed
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.	2001-02	11218067
Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells.	2000-10	11030734
Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines.	2000-02	10683202
Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus.	1998-06	9603189
Cloning and expression of human 5-HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase.	1997-10-20	9351641
[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors.	1997-04-01	9225293
Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor.	1996-11-25	8946946
[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor.	1996-05-23	8813606
The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.	1995-06-15	7796807

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:26:40 GMT 2025` Edited by `admin` on `Mon Mar 31 19:26:40 GMT 2025`
Record UNII	9073C0W4E9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Renzapride

Official Name

English

ATL-1251

Preferred Name

English

BRL 24924A

Code

English

Renzapride [WHO-DD]

Common Name

English

BRL-24924A

Code

English

RENZAPRIDE [MI]

Common Name

English

REL-4-AMINO-N-(1R,4S,5R)-1-AZABICYCLO(3.3.1)NON-4-YL-5-CHLORO-2-METHOXYBENZAMIDE

Common Name

English

((±)-ENDO)-4-AMINO-N-(1-AZABICYCLO(3.3.1)NON-4-YL)-5-CHLOROANISAMIDE

Common Name

English

BRL-24924

Common Name

English

renzapride [INN]

Common Name

English

RENZAPRIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C267